N/A
N=25
Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections
Tendinopathy · Rheumatic Diseases
Bottom Line
View on ClinicalTrials.gov: NCT01200875 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcome: Primary: Blood Growth Factor Concentrations — 1.078 IGF-1 fold-change from baseline @ 24h
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Ultrasound-guided platelet-rich-plasma (PRP) injection (Procedure); Platelet-Rich Plasma (PRP) (Procedure)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Growth Factor Concentrations |
1.078 | — |
Summary
Platelet-Rich Plasma (PRP) has been banned in competitive athletes because some people think it may enhance athletic performance. However, there is very little published research to support or undermine this point of view. The purposes of this study are: (1) To assess the effects of local platelet-rich plasma (PRP) therapy on systemic levels of growth factors with suspected or known performance-enhancing effects; and (2) To understand whether the effect of PRP therapy on these growth factors differs between intramuscular and intratendinous PRP injections.
This research study is looking for 40 people who are receiving platelet-rich plasma therapy for a tendon or muscle injury. The study involves collecting seven blood samples (2 teaspoons each) from each patient, before and after the PRP treatment. Blood samples may be donated at any location of the patient's choosing, and participants will be paid for their time.
Eligibility Criteria
Inclusion Criteria
- Male and female patients 18-50 years old, receiving ultrasound-guided intratendinous or intramuscular PRP injections
Exclusion Criteria
- History of cancer, diabetes, hormone-replacement therapy, or abnormal nutritional habits.
- Contraindications for PRP therapy itself:
- preexisting coagulation defects including thrombocytopenia
- hypofibrinogenemia
- anticoagulation medications
- hypersensitivity to bovine products, which may be used for platelet activation.
Data sourced from ClinicalTrials.gov (NCT01200875). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.